The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The company says the platform offers improved manufacturability and functional advantages
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Subscribe To Our Newsletter & Stay Updated
